Tower Research Capital (TRC)’s Theriva Biologics TOVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1 Buy
+5
New +$1 ﹤0.01% 5879
2025
Q1
– Sell
-1,391
Closed -$2.44K – 5790
2024
Q4
$2.44K Buy
1,391
+730
+110% +$1.07K ﹤0.01% 4840
2024
Q3
$912 Buy
661
+655
+10,917% +$3.2K ﹤0.01% 5232
2024
Q2
$34 Hold
6
– – ﹤0.01% 5555
2024
Q1
$68 Hold
6
– – ﹤0.01% 5687
2023
Q4
$62 Hold
6
– – ﹤0.01% 5754
2023
Q3
$78 Hold
6
– – ﹤0.01% 5749
2023
Q2
$145 Hold
6
– – ﹤0.01% 5779
2023
Q1
$0 Hold
6
– – ﹤0.01% 6274
2022
Q4
$0 Sell
6
-9
-60% -$163 ﹤0.01% 6379
2022
Q3
$0 Sell
15
-29
-66% -$1.11K ﹤0.01% 6493
2022
Q2
$2K Buy
44
+5
+13% +$286 ﹤0.01% 5605
2022
Q1
$3K Sell
39
-198
-84% -$13.5K ﹤0.01% 5423
2021
Q4
$16K Buy
237
+184
+347% +$17.4K ﹤0.01% 3937
2021
Q3
$6K Buy
53
+42
+382% +$5.23K ﹤0.01% 4776
2021
Q2
$2K Buy
+11
New +$1.58K ﹤0.01% 5078
2021
Q1
– Sell
-59
Closed -$11.7K – 5730
2020
Q4
$6K Buy
+59
New +$5.17K ﹤0.01% 4563
2020
Q3
– Hold
0
– – – 5091
2020
Q2
– Hold
0
– – – 4999
2020
Q1
– Hold
0
– – – 3885
2019
Q4
– Hold
0
– – – 4360
2019
Q3
– Hold
0
– – – 4510
2019
Q2
– Hold
0
– – – 4295
2019
Q1
– Hold
0
– – – 4275
2018
Q4
– Hold
0
– – – 4348
2018
Q3
– Hold
0
– – – 4247
2018
Q1
– Hold
0
– -$1K – 3821
2017
Q4
– Hold
0
– – – 3369
2017
Q3
– Sell
-3
Closed -$17.3K – 3675
2017
Q2
$13K Sell
3
-11
-79% -$54.8K ﹤0.01% 1464
2017
Q1
$76K Buy
14
+13
+1,300% +$90.7K 0.01% 553
2016
Q4
$6K Buy
+1
New +$10.3K ﹤0.01% 2967
2016
Q3
– Hold
0
– – – 4445
2016
Q2
– Hold
0
– – – 4966
2016
Q1
– Hold
0
– – – 3784
2015
Q4
– Hold
0
– – – 4167
2015
Q3
– Hold
0
– – – 2576
2015
Q2
– Hold
0
– – – 2825
2015
Q1
– Hold
0
– – – 3601
2014
Q4
– Hold
0
– – – 3161
2014
Q3
– Hold
0
– – – 3460
2014
Q2
– Hold
0
– – – 3760
2014
Q1
– Hold
0
– – – 3467

Other funds holding TOVX

Tower Research Capital (TRC)'s TOVX Position: Q3 2026 in Review

Tower Research Capital (TRC) opened a new position in Theriva Biologics (TOVX) in Q3 2026: 5 shares worth $1. The stake represents ﹤0.01% of the portfolio and ranks #5879 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in TOVX as recently as Q4 2024.

Tower Research Capital (TRC) first reported a position in TOVX in Q4 2016 and has held it in 20 quarters since. The position peaked at $76K in Q1 2017. 26 funds tracked by Wall St. Rank hold TOVX as of Q3 2026.

  • Tower Research Capital (TRC) held 5 shares of Theriva Biologics worth $1 as of Q3 2026.
  • Theriva Biologics was a new Tower Research Capital (TRC) position in Q3 2026.
  • Theriva Biologics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #5879 holding.
  • Tower Research Capital (TRC) first reported a position in Theriva Biologics in Q4 2016 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Theriva Biologics position peaked at $76K in Q1 2017.
  • 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.